Literature DB >> 23040222

Treatment-related morbidity in prostate cancer: a comparison of 3-dimensional conformal radiation therapy with and without image guidance using implanted fiducial markers.

Jasmeet Singh1, Peter B Greer, Martin A White, Joel Parker, Jackie Patterson, Colin I Tang, Anne Capp, Christopher Wratten, James W Denham.   

Abstract

PURPOSE: To estimate the prevalence of rectal and urinary dysfunctional symptoms using image guided radiation therapy (IGRT) with fiducials and magnetic resonance planning for prostate cancer. METHODS AND MATERIALS: During the implementation stages of IGRT between September 2008 and March 2010, 367 consecutive patients were treated with prostatic irradiation using 3-dimensional conformal radiation therapy with and without IGRT (non-IGRT). In November 2010, these men were asked to report their bowel and bladder symptoms using a postal questionnaire. The proportions of patients with moderate to severe symptoms in these groups were compared using logistic regression models adjusted for tumor and treatment characteristic variables.
RESULTS: Of the 282 respondents, the 154 selected for IGRT had higher stage tumors, received higher prescribed doses, and had larger volumes of rectum receiving high dosage than did the 128 selected for non-IGRT. The follow-up duration was 8 to 26 months. Compared with the non-IGRT group, improvement was noted in all dysfunctional rectal symptoms using IGRT. In multivariable analyses, IGRT improved rectal pain (odds ratio [OR] 0.07 [0.009-0.7], P=.02), urgency (OR 0.27 [0.11-0.63], P=<.01), diarrhea (OR 0.009 [0.02-0.35], P<.01), and change in bowel habits (OR 0.18 [0.06-0.52], P<.010). No correlation was observed between rectal symptom levels and dose-volume histogram data. Urinary dysfunctional symptoms were similar in both treatment groups.
CONCLUSIONS: In comparison with men selected for non-IGRT, a significant reduction of bowel dysfunctional symptoms was confirmed in men selected for IGRT, even though they had larger volumes of rectum treated to higher doses. Crown
Copyright © 2013. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23040222     DOI: 10.1016/j.ijrobp.2012.07.2376

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  21 in total

Review 1.  Current status and future prospects of multi-dimensional image-guided particle therapy.

Authors:  Shinichiro Mori; Silvan Zenklusen; Antje-Christin Knopf
Journal:  Radiol Phys Technol       Date:  2013-02-19

Review 2.  Fiducial marker guided prostate radiotherapy: a review.

Authors:  Angela G M O'Neill; Suneil Jain; Alan R Hounsell; Joe M O'Sullivan
Journal:  Br J Radiol       Date:  2016-09-23       Impact factor: 3.039

3.  A comparison of clinical outcomes between three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer.

Authors:  Takuya Shimizuguchi; Keiji Nihei; Tomoyuki Okano; Yumiko Machitori; Kei Ito; Katsuyuki Karasawa
Journal:  Int J Clin Oncol       Date:  2016-10-24       Impact factor: 3.402

4.  Reduced late urinary toxicity with high-dose intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer.

Authors:  A Zapatero; M Roch; D Büchser; P Castro; L Fernández-Banda; G Pozo; O Liñán; C Martin de Vidales; A Cruz-Conde; F García-Vicente
Journal:  Clin Transl Oncol       Date:  2017-04-03       Impact factor: 3.405

Review 5.  The prostate cancer focal therapy.

Authors:  Filippo Pesapane; Francesca Patella; Enrico Maria Fumarola; Edoardo Zanchetta; Chiara Floridi; Gianpaolo Carrafiello; Chloë Standaert
Journal:  Gland Surg       Date:  2018-04

6.  Infections after fiducial marker implantation for prostate radiotherapy: are we underestimating the risks?

Authors:  Jasmin Loh; Katie Baker; Swetha Sridharan; Peter Greer; Chris Wratten; Anne Capp; Sarah Gallagher; Jarad Martin
Journal:  Radiat Oncol       Date:  2015-02-13       Impact factor: 3.481

7.  A pilot study of EUS-guided fiducial insertion for the multidisciplinary management of gastric cancer.

Authors:  Sujievvan Chandran; Rhys Vaughan; Marios Efthymiou; Joseph Sia; Christopher Hamilton
Journal:  Endosc Int Open       Date:  2014-07-18

Review 8.  The potential role of magnetic resonance spectroscopy in image-guided radiotherapy.

Authors:  Mai Lin Nguyen; Brooke Willows; Rihan Khan; Alexander Chi; Lyndon Kim; Sherif G Nour; Thomas Sroka; Christine Kerr; Juan Godinez; Melissa Mills; Ulf Karlsson; Gabor Altdorfer; Nam Phong Nguyen; Gordon Jendrasiak
Journal:  Front Oncol       Date:  2014-05-05       Impact factor: 6.244

Review 9.  Potential applications of image-guided radiotherapy for radiation dose escalation in patients with early stage high-risk prostate cancer.

Authors:  Nam P Nguyen; Rick Davis; Satya R Bose; Suresh Dutta; Vincent Vinh-Hung; Alexander Chi; Juan Godinez; Anand Desai; William Woods; Gabor Altdorfer; Mark D'Andrea; Ulf Karlsson; Richard A Vo; Thomas Sroka
Journal:  Front Oncol       Date:  2015-02-02       Impact factor: 6.244

10.  Image guided hypofractionated radiotherapy by helical tomotherapy for prostate carcinoma: toxicity and impact on Nadir PSA.

Authors:  Salvina Barra; Stefano Vagge; Michela Marcenaro; Gladys Blandino; Giorgia Timon; Giulia Vidano; Dario Agnese; Marco Gusinu; Francesca Cavagnetto; Renzo Corvò
Journal:  Biomed Res Int       Date:  2014-03-18       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.